TY - JOUR
T1 - Development of bedaquiline nanoemulsions intended for paediatric multidrug-resistant tuberculosis
T2 - excipient selection and preformulation studies
AU - Ajayi, Taiwo Oreoluwa
AU - Poka, Madan Sai
AU - Witika, Bwalya Angel
N1 - Publisher Copyright:
2024 Ajayi, Poka and Witika.
PY - 2024
Y1 - 2024
N2 - Preformulation investigations into the development of drug formulations, encompassing considerations related to the structure of the drug, excipients, composition, and physical attributes are crucial. This phase is pivotal in ensuring the ultimate success of nanoemulsion development. The objective of this study was to evaluate and define the properties of bedaquiline (BDQ) and the necessary excipients for the formulation of self-emulsifying BDQ-loaded nanoemulsions. To determine the saturation solubility of BDQ in various oils, an in-house validated HPLC method was used. Fourier transform infrared spectroscopy was utilised to identify and evaluate the compatibility between BDQ and the selected excipients. The water titration method was used to construct phase diagrams to identify the type of structure that resulted following emulsification and to characterise the behaviour of mixtures along dilution paths. The solubility studies revealed that BDQ exhibited the highest solubility in olive oil, with a solubility of 3.45 ± 0.041 mg/ml. The design space led to the formation of emulsions categorised as Winsor products. Importantly, the FTIR data indicated the absence of any potential interactions between BDQ and the chosen excipients. The preformulation studies were successful and facilitated the selection of compatible and suitable excipients for the formulation of BDQ-loaded nanoemulsions.
AB - Preformulation investigations into the development of drug formulations, encompassing considerations related to the structure of the drug, excipients, composition, and physical attributes are crucial. This phase is pivotal in ensuring the ultimate success of nanoemulsion development. The objective of this study was to evaluate and define the properties of bedaquiline (BDQ) and the necessary excipients for the formulation of self-emulsifying BDQ-loaded nanoemulsions. To determine the saturation solubility of BDQ in various oils, an in-house validated HPLC method was used. Fourier transform infrared spectroscopy was utilised to identify and evaluate the compatibility between BDQ and the selected excipients. The water titration method was used to construct phase diagrams to identify the type of structure that resulted following emulsification and to characterise the behaviour of mixtures along dilution paths. The solubility studies revealed that BDQ exhibited the highest solubility in olive oil, with a solubility of 3.45 ± 0.041 mg/ml. The design space led to the formation of emulsions categorised as Winsor products. Importantly, the FTIR data indicated the absence of any potential interactions between BDQ and the chosen excipients. The preformulation studies were successful and facilitated the selection of compatible and suitable excipients for the formulation of BDQ-loaded nanoemulsions.
KW - drug delivery
KW - nanoemulsions (NE)
KW - paediatric
KW - preformulation compatibility
KW - solubility studies
KW - tuberculosis
UR - http://www.scopus.com/inward/record.url?scp=85196653000&partnerID=8YFLogxK
U2 - 10.3389/fmedt.2024.1388113
DO - 10.3389/fmedt.2024.1388113
M3 - Article
C2 - 38915350
AN - SCOPUS:85196653000
SN - 2673-3129
VL - 6
JO - Frontiers in Medical Technology
JF - Frontiers in Medical Technology
M1 - 1388113
ER -